DexCom, Inc. DXCM
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, DexCom, Inc. gets an algorithmic score of 78/100. It trades at 86.64 $, with a bullish technical trend (RSI 48.7) and 39.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (38.5%): generates strong profit on equity.
- High net margin (20.1%): pricing power / competitive advantage.
- Sustained revenue growth (17.0% compound annual).
- Low beta (0.53): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 34.25 |
| Forward P/E | 27.73 |
| PEG | 1.35 |
| P/B | 12.47 |
| EV/EBITDA | 22.91 |
| P/S | 6.58 |
| ROE % | 38.49 |
| ROA % | 10.33 |
| Gross margin % | 62.47 |
| Operating margin % | 24.33 |
| Net margin % | 20.12 |
| Revenue growth % (y/y) | 13.10 |
| Earnings growth % (y/y) | 43.60 |
| Revenue CAGR % | 17.01 |
| Earnings CAGR % | 34.83 |
| Debt/Equity % | 53.35 |
| Current ratio | 1.73 |
| FCF yield % | 3.29 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -4.6 % |
| 3 months | +28.6 % |
| 6 months | +40.0 % |
| YTD | +30.2 % |
| 1 year | +29.1 % |
| 3 years | -1.0 % |
| 5 years | -37.4 % |
Risk
| 1-year volatility | 39.5 % |
| Beta | 0.53 |
| 5-year max drawdown | -66.3 % |
| Sharpe 1A | 0.74 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.